DELFI Diagnostics Unveils Groundbreaking Data on Blood-Based Lung Cancer Screening at ATS 2026

DELFI Diagnostics Presents Innovative Data on Lung Cancer Screening

DELFI Diagnostics, a leader in developing blood-based cancer detection tests, made waves at the ATS 2026 International Conference held from May 15-20 in Orlando, FL. This event marked a pivotal moment for lung cancer screening as DELFI showcased significant clinical utility data from their groundbreaking blood test, FirstLook™ Lung.

The highlight of the conference was the late-breaking oral presentation of the L301 Clinical Utility Study, known as the FIRSTLUNG study. This research aimed at evaluating whether integrating a blood-based lung cancer test increases the overall screening rates compared to traditional methods like low-dose computed tomography (LDCT). Running under the expertise of Dr. James Davis from Duke University, the FIRSTLUNG trial stands unique as the first interventional study to assess the clinical utility of a blood test in the lung cancer screening process.

Lung cancer continues to be a pressing health concern, being the leading cause of cancer-related deaths in the United States. Despite recommendations for annual screenings, it's alarming that only about 20% of eligible Americans participate. DELFI’s FirstLook Lung is positioned to bridge this gap, offering a non-invasive, accessible testing option that aligns seamlessly with routine blood work.

During the ATS session, various presentations were delivered. They not only emphasized DELFI’s innovative technology but also underscored real-world implementation data and the feasibility of at-home blood collection, particularly focusing on underserved communities. All five presentations raised critical questions about the effectiveness of blood-based tests in changing clinical practices and expanding access to necessary screenings for those in need.

Susan Tousi, CEO of DELFI Diagnostics, noted, "The data we shared at ATS signify a transformative moment for lung cancer screening. For the first time, we possess clinical evidence that affirmatively shows blood-based testing influences screening uptake. It's promising to see that FirstLook Lung not only validates analytically but also impacts clinical behavior by reaching previously unscreened populations."

Among the various presentations featured, the late-breaking oral presentation stood out: "A Cluster Randomized Interventional Study of a Blood-Based Lung Cancer Screening Test in Primary Care Practices." It effectively shows that offering a blood test alongside standard screenings could potentially increase patient engagement and compliance with lung cancer screening efforts.

Further discussions tackled societal barriers to screening, including socioeconomic factors affecting accessibility. DELFI's initiative is indicative of a broader trend aiming to make early cancer detection more equitable and widespread. As the health care landscape evolves, the integration of innovative technologies like those developed by DELFI is critical.

Dr. James Davis shared broader implications of using blood tests for lung cancer screening, asserting that such innovations could make screening considerably easier for primary care providers and their patients. By streamlining the process of receiving various diagnostics, the likelihood of eligible individuals participating in screenings could significantly rise.

Attendees were invited to visit DELFI at Booth #2431 to learn more about the FirstLook Lung test and the promise it holds for the future of lung cancer screening. This development by DELFI Diagnostics is hoped to pave the way for more accessible and effective cancer detection methods, demonstrating how technological advances can lead to better health outcomes for all.

As DELFI continues to pursue partnerships with health systems and explore EMR integration, the prospects of blood-based lung cancer screening becoming standard practice look optimistic.

To discover more about DELFI Diagnostics, their innovative technology, and their commitment to improving lung cancer screening, visit www.delfidiagnostics.com.